Background. Bacterial vaginosis (BV) recurrence posttreatment is common. Our aim was to determine if behaviors were associated with BV recurrence in women in a randomized controlled trial (RCT).
sequencing methods have advanced our understanding of this complex polymicrobial condition, with high bacterial species diversity reported in women with BV compared to normal flora, and increasing numbers of specific noncultivable BVassociated bacteria (BVAB) being described [3] . Two of the commonest BVAB, Gardnerella vaginalis and Atopobium vaginae, contribute to a vaginal biofilm associated with BV, which rapidly reaccumulates following antibiotic therapy [4, 5] .
Epidemiologic studies consistently report an association between BV and sexual activity. In a study of young women, BV was strongly associated with penile-vaginal sex, was rare in women only engaging in noncoital practices, and was absent in women reporting no sexual contact with others [6] . BV was associated with increased numbers of sexual partners and inconsistent condom use in a meta-analysis [7] , and BVAB and BV-associated biofilms have been detected in the male coronal sulcus and urine [8] [9] [10] . Most researchers concur that BV is associated with sexual activity, but whether this is because of transmission of BVAB between partners or because sexual activity adversely impacts on colonization with protective Lactobacillus species is unknown [11] .
One of the challenges facing clinicians is provision of effective BV treatment, as long-term efficacy of recommended antibiotics is poor and relapse is common [12, 13] . Treatment trials have yielded mixed results regarding the contribution of posttreatment sexual activity to BV recurrence. In a study of 121 women following oral metronidazole treatment, 58% recurred within 12 months. Recurrence was associated with having a regular sexual partner (RSP) or a female sexual partner (FSP), not using hormonal contraception, and history of BV [12] . Sanchez et al found that interim unprotected intercourse was associated with BV recurrence [14] , and Schwebke et al reported that abstaining from sex/consistent condom use reduced recurrence by 50% [15] . In contrast, in women who have sex with women (WSW), Marrazzo et al found that recurrence was not associated with posttreatment sexual activity, but with baseline and posttreatment detection of specific BVAB [16] .
Current approaches to the management of BV are clearly suboptimal, with reliance on antibiotics that cure less than half the treated population. We sought to determine the behavioral and contraceptive factors associated with BV recurrence in an analysis of a double-blind, placebo-controlled treatment trial, in which combination oral and vaginal therapies did not improve recurrence rates over metronidazole alone [17] . Our hypothesis was that BV recurrence is significantly influenced by sexual and behavioral practices.
METHODS
This was a double-blind, placebo-controlled, parallel-group trial with balanced randomization (3 arms, 1:1:1) conducted in 450 women from December 2007 through May 2010 at Melbourne Sexual Health Centre, Australia [17] . Participants received 400 mg of oral metronidazole twice daily for 7 days and were randomized to 1 of 3 vaginal interventions: placebo, 2% clindamycin cream, or a commercially available estrioland Lactobacillus-containing probiotic. This study has been described in detail elsewhere [17] . In brief, 18-to 50-year-old women were eligible if they had abnormal vaginal discharge or odor with ≥3 Amsel criteria and a Nugent score (NS) = 4-10. Women were ineligible if positive for human immunodeficiency virus (HIV), pregnant, breastfeeding, or unable to use condoms/abstain from sex during vaginal treatment.
At baseline, participants were examined by a clinician, Nugent and Amsel scores were documented, and paper-based questionnaires were completed recording demographic, behavioral, clinical, and contraceptive data. After treatment, women completed questionnaires and self-collected vaginal smears and returned specimens by mail at 1, 2, 3, and 6 months or until BV recurrence. The primary endpoint was BV recurrence, defined as an NS of 7-10 at any interval after treatment, at which point participants were offered retreatment. Behavioral data were recorded for the interval preceding each NS. "Same pre-/posttreatment RSP" was defined as having the same sexual partner pretreatment and in the 2 months after treatment. Smears were scored by 1 of 3 blinded microbiologists experienced in the Nugent method [17] . Women providing ≥2 sets of microbiological and behavioral data (follow-up data on ≥1 occasions) were included in longitudinal analyses. Specimens not returned by interval midpoint, or at 6 months if >210 days after enrollment, were considered missing, and participants who did not return specimens were deemed lost to follow-up. Data were censored when participants experienced BV recurrence, reached 210 days, or were lost to follow-up.
Statistical Methods and Ethical Approval
Frequencies and 95% confidence intervals (CIs) of baseline demographic, clinical, and behavioral data were analyzed using Stata software 12.0 (StataCorp LP). The rate per 100 person-years of BV recurrence for selected variables was calculated along with Poisson 95% CIs. Cox regression estimated hazard ratios (HRs) for the risk of BV recurrence associated with baseline and longitudinal characteristics. Characteristics/ exposures that changed during the study period were reconstructed based on questionnaire data from each study interval and examined in a number of ways including "present" or "absent" and "current/recent" or "not recent" exposure. Multivariate cox regression models were used to assess whether these characteristics were predictors of BV as time-dependent covariates. Models were built sequentially starting with the characteristic most strongly associated with BV by univariate analysis and continued until no other variable reached significance. Univariate and multivariate analyses were stratified for treatment group. As condom use and frequency of sex were moderately correlated, we built 3 multivariate models: 2 containing one of the correlated variables, the third with both. Sensitivity analyses were performed adjusting for treatment group, and with and without age. A level of P < .05 was considered statistically significant. This trial was approved by the Human Research and Ethics Committees of the Alfred Hospital and Monash University, Melbourne, Australia, with written informed consent obtained from participants.
RESULTS
Of the 450 volunteers, 46 provided no postrandomization data and were excluded. Postrandomization NS and behavioral data were available for 404 (90%) women, who contributed 152 person-years of follow-up (median, 103 days; no difference between treatment groups, P = .90). Fifty-seven participants (13%) without BV recurrence did not complete 6 months of follow-up, but contributed person-time to survival analyses as non recurrent cases based on their last NS. At baseline, the majority of women had an NS = 7-10 (84%); 64 (16%) had an NS = 4-6 and ≥3 Amsel criteria (Table 1) . Over the course of 6 months, 115 women (28%) experienced BV recurrence; there was no difference in recurrence of BV or abnormal flora between treatment arms [17] .
Demographic, Behavioral, and Clinical Characteristics of the Study Population
The median age of participants was 27 years (range, 17-49 years; Table 2 ). Most women had a tertiary education (64%) and were born in Australia or New Zealand (62%), with the remainder born in China or Southeast Asia (35%), Britain or Ireland (20%), Eastern or Western Europe (17%), and North America (16%). A history of BV was reported by 193 (49%) women, 174 (43%) were current smokers, and 105 (26%) douched. Condoms were the main contraceptive method for 171 (43%) women, and 110 (28%) used an estrogen-containing method of contraception (ECC). A history of chlamydia (29%), genital warts (18%), herpes (14%), and abnormal cervical cytology (27%) was common, whereas gonorrhoea was rare (2%).
In the prior 12 months, 197 (49%) women reported having ≥2 male sexual partners (MSPs) and 84 (21%) reported having ≥1 FSP; the majority reported penile-vaginal (91%) and receptive oral (90%) sex (Table 3) . Two hundred seventytwo women (68%) had an RSP at randomization; of these, 252 (93%) were MSPs and 20 (7%) were FSPs. Among women with an RSP, 225 (83%) had ongoing vaginal and/or receptive oral sex with the same pretreatment RSP in the 2 months after treatment; 211 (94%) with MSPs and 14 (6%) with FSPs. Few (16%) participants reported consistent condom use for penilevaginal sex in the 3 months prior to enrollment. Sixty-one participants (15%) were sex workers.
Demographic and Behavioral Factors Associated With BV Recurrence
Univariate analysis of baseline and longitudinal characteristics associated with BV recurrence, stratified by treatment group, are described in Table 4 . Baseline characteristics associated with recurrence included being born outside Australia/New Zealand (HR = 1.48; 95% CI, 1.02-2.15), having a baseline RSP (HR = 1.72; 95% CI, 1.12-2.64), and ECC use (HR = 0.57; 95% CI, .37-.87). Age, education, treatment, and history of BV were not associated with recurrence. No other baseline behaviors were associated with recurrence, including number of MSPs or FSPs; vaginal, anal, or receptive oral sex in the last 12 months; or inconsistent condom use for vaginal or anal sex in the last 3 months.
Longitudinal univariate posttreatment practices and behaviors associated with BVrecurrence (Table 4) Unadjusted hazard ratios are stratified by treatment group, bolded text indicates significant associations at the level p < 0.05.
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; ECC, estrogen-containing contraceptive; HR, hazard ratio; py, person-years; RSP, regular sexual partner. a Each variable is comprised of behaviors reported longitudinally by participants at each study interval.
b Receptive oral sex is defined as being given oral sex.
c Or no penile-vaginal sex.
d Same pre-/posttreatment RSP, defined as same sexual partner pretreatment and in the 2 months posttreatment.
2.99)
, and having the same pre-/posttreatment RSP (male or female) (HR = 1.84; 95% CI, 1.25-2.73). Current or recent use of an ECC (oral contraceptive pill = 108, NuvaRing = 2) was protective against BV recurrence (HR = 0.62; 95% CI, .40-.95). Of the 110 women using an ECC at baseline, 80 (72%) had continuous ECC use, and 30 (28%) inconsistent ECC use during follow-up. Because ovulation can be delayed for several months after ceasing ECC, ECC use was analyzed longitudinally as "current/recent" or "not recent." Few women (n = 33) used progesterone-only methods of contraception, which limited our power to examine their association with recurrence; however, use of any hormonal contraception was not significantly protective against recurrence (HR = 0.83; 95% CI, .56-1.24). We explored the association between BV recurrence and frequency of sexual activity with partners (male and female) and then with frequency of penile-vaginal sex alone. Compared with no sexual activity, sexual contact with partners ≤4 times per month or >4 times per month was associated with recurrence (HR = 2.18; 95% CI, 1.19-4.01 and HR = 1.96; 95% CI, 1.09-3.52, respectively); however, there was no dose response between increased frequency of sexual activity and risk of recurrence. Frequency of penile-vaginal sex and/or any sexual activity with MSPs and FSPs were examined as continuous variables and at a number of cut points: there was no significant association with increased sexual activity and increased risk of recurrence using these methods (data not shown). No association was found between BV recurrence and a new sexual partner, FSPs, smoking, douching, or engaging in sex work.
Factors associated with BV recurrence by univariate analysis were included in multivariate analyses and stratified for treatment group. This included country of birth, ECC use, same pre-/posttreatment RSP, and condom use for penile-vaginal sex (Table 5) . Age was included owing to reported associations with BV and sexual/contraceptive practices. Frequency of sexual activity was included to determine whether it exerted an independent effect on recurrence after adjusting for RSP. Bolded text indicates significant associations at the level p < 0.05.
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; ECC, estrogen-containing contraceptive; HR, hazard ratio; py, person-years; RSP, regular sexual partner. a All models are stratified for treatment.
b Same pre-/posttreatment RSP defined as same sexual partner pretreatment and in the 2 months posttreatment.
d Sex with females is defined as having received oral sex, sex with males is defined as penile-vaginal sex.
As frequency of sex and condom use were moderately correlated (r = 0.66, P < .001), 3 multivariate analyses were conducted; 2 contained one of the correlated variables, and one included both variables. Multivariate models were stratified for treatment group, but sensitivity analyses were also performed adjusting for treatment group, and with and without age, yielding similar results (data not shown). Model 1 includes the variables most strongly associated with BV recurrence, and demonstrates that having the same pre-/posttreatment RSP (adjusted HR [AHR] = 1.77; 95% CI, 1.14-2.73) and inconsistent condom use for penile-vaginal sex with any MSP (AHR = 1.74; 95% CI, 1.12-2.70) were associated with BV recurrence, whereas ECC use was protective (AHR = 0.51; 95% CI, .33-.78). Being born outside Australia/ New Zealand showed a modest association with recurrence (AHR = 1.49; 95% CI, 1.03-2.17). The second model included frequency of sex and omitted the correlated "condom use" variable. This analysis showed that frequency of sexual activity was not associated with recurrence, exposure to the same pre-/ posttreatment RSP conferred an increased risk (AHR = 1.99; 95% CI, 1.25-3.18), and ECC use halved the risk (AHR = 0.56; 95% CI, .36-.87) of recurrence. The final model included all variables and confirmed that after adjusting for frequency of sexual activity, having the same pre-/posttreatment RSP (AHR = 1.91; 95% CI, 1.19-3.07), inconsistent condom use for penile-vaginal sex (AHR = 1.85; 95% CI, 1.04-3.29) and being born outside Australia/New Zealand (AHR = 1.46; 95% CI, 1.01-2.13) were associated with BV recurrence, whereas ECC use was protective (AHR = 0.52; 95% CI, .34-.81).
DISCUSSION
In this trial, posttreatment sexual and contraceptive behaviors were strongly associated with BV recurrence. Importantly, exposure to the same pre-/posttreatment RSP, and inconsistent condom use for penile-vaginal sex, nearly doubled the risk of BV recurrence, whereas the use of an estrogen-containing contraceptive method halved the risk. These data provide compelling evidence that behavioral and contraceptive practices play a significant role in modifying the effectiveness of current antibiotics in the treatment of BV.
The association between exposure to an ongoing RSP and recurrence is supported by a previous study in which women who remained with their pretreatment RSP had a 3-fold increased risk of BV recurrence [12] . The robustness of the association between recurrence and exposure to an RSP across 3 multivariate models, and the fact that it remained after adjusting for frequency of sexual activity, condom use, and other potentially confounding behavioral factors, indicates that ongoing exposure to an RSP significantly contributes to BV recurrence in this cohort, and importantly, that more frequent sexual activity does not explain this association. Increased frequency of sexual activity has been proposed as a mechanism by which normal vaginal flora is disrupted. Studies have found an association between frequency of penile-vaginal, digital-vaginal, toyvaginal, or receptive oral sex, and unfavorable vaginal states including unstable vaginal flora [18] , BV [19] , reduction in hydrogen peroxide-producing lactobacilli [11, 20, 21] , and increased colonization with G. vaginalis [11] ; however, others report that higher frequency of penile-vaginal sex increases concentrations of protective hydrogen peroxide-producing lactobacilli [11] .
Inconsistent condom use for penile-vaginal sex was strongly associated with BV recurrence, and remained so after controlling for an RSP and other behaviors. This finding is consistent with previous studies [14, 15] , and a meta-analysis showing a 20% protective effect of consistent condom use against BV [7] . Other data support the concept that exposure to male genitalia contributes to the development of BV in heterosexual women. Wives of circumcised males in a Ugandan circumcision trial had a significantly reduced risk of BV (adjusted prevalence risk ratio = 0.60; 95% CI, .38-.94) compared to wives of uncircumcised males [22] . Furthermore, male circumcision has been associated with a significant reduction in penile anaerobic microbial flora, including BV-associated genera Clostridiales and Prevotellaceae [9] . Pyrosequencing of the microbiota of the coronal sulcus and distal urethra in adolescents [23] showed these sites to be colonized by BVAB, with the composition of the coronal sulcus microbiota influenced by circumcision and sexual activity [23] . Male carriage of G. vaginalis, an organism considered to be integral in the development of BV, is commonly reported [10, 24, 25] .
This trial was conducted in a population of sexually active women who predominantly had sex with men. Numbers of posttreatment FSPs were too small to examine the contribution of female partnerships to recurrence. Importantly, there is increasing evidence to support exchange of vaginal flora and BVAB between WSW. WSW have been shown to have high levels of concordant vaginal flora with their FSP [26, 27] , and Lactobacillus species are shared between FSPs [28] . We previously reported that women with a posttreatment FSP had a 3-fold increased risk of BV recurrence [12] . Although Marrazzo et al found that BV recurrence was not associated with posttreatment sexual activity in WSW [16] , this group recently reported that vaginal-toy use was associated with higher likelihood of colonization with G. vaginalis [11] and digital-vaginal and oral-vaginal sex with reduced load of L. crispatus [21] . They hypothesized that some protective commensal species could be particularly sensitive to the effects of sexual activity.
Estrogen-containing contraception, predominantly the oral contraceptive pill in this cohort, showed a significantly protective effect against BV recurrence after adjusting for confounding factors including condom use and RSP. A number of cross-sectional studies have reported hormonal contraceptives, mainly combined, to be protective against prevalent [29] [30] [31] , incident [32, 33] , and recurrent [12, 31] BV, with a some studies also reporting that progesterone-only methods may be associated with a reduced risk for incident [33] and recurrent [31] BV. One mechanism by which combined contraceptives may be protective is that estrogen increases the glycogen-content of epithelial cells, which is a substrate for Lactobacillus species for the generation of lactic acid, a known potent inhibitor of BV [34, 35] . Hormonal contraceptives, particularly progesterone-only, may also reduce heme availability for anaerobes such as G. vaginalis through reduction in menstruation. Interestingly, BV is most commonly reported at the beginning of the menstrual cycle when estradiol levels are lowest [36, 37] , and higher rates of remission occur in pregnancy [38] . Contraceptive use may also affect immunological factors, with Cherpes et al reporting that hormonal contraceptive use was associated with altered vaginal immunity in BV [39] .
This study has a number of limitations. Sexual practices are often highly correlated, making it difficult to attribute an association to a specific behavior and to infer causality. Even though the association between exposure to the same RSP and BV recurrence remained in all 3 models after adjusting for potentially confounding factors, we cannot exclude the effect of unmeasured confounding. Secondly, we did not have sufficient power to examine the effect of less common behaviors on recurrence, such as female partners and progesterone-only contraceptives. Although sufficiently common to be assessed, there was no association between BV recurrence and risk factors previously associated with BV including history of BV, smoking, douching, and sex work. Self-sampling was employed to optimize participant retention, we were therefore limited in our outcome measure to the use of the Nugent method, which potentially underestimated BV recurrence by classifying women with an NS of 4-6 but ≥3 Amsel criteria as cured. The strengths of our trial include that it was a large RCT with high retention rates and detailed epidemiologic data matched to frequent sampling over 6 months. This minimized participant recall bias and enabled accurate assessment of associations between recent behaviors and relevant NSs and longer-term BV recurrence. We applied the gold-standard Nugent method to ensure generalizability of our findings, and have an ongoing quality-assurance program to ensure consistency between our experienced microbiologists.
A striking aspect to clinical management of BV is that 1-month cure rates of recommended therapies are 70%-80%; however, by 3-12 months, failure rates approach 50% [12, 13] . Our data indicate that the long-term poor performance of recommended therapies may at least partly be attributed to posttreatment sexual and contraceptive behaviors. Whether the association with RSP is due to reinfection/transmission of BVAB from untreated RSPs, another "RSP factor" that hinders recolonization after treatment with protective Lactobacillus species, or unmeasured confounding remains unanswered. Although 5 of 6 partner treatment trials failed to reduce BV recurrence in women, systematic review has shown that these trials were significantly flawed [40] . These data raise the tantalizing question of whether partner treatment trials in heterosexual and WSW populations need revisiting. Importantly for clinicians, it appears that potentially modifiable practices, such as use of condoms and/or estrogen-containing contraceptives, may provide a degree of protection against recurrence. As current therapeutic approaches have limited impact on longterm BV cure, we need to understand the mechanisms by which these practices modify the risk of BV recurrence, and to more formally assess such interventions to determine the degree to which they impact on BV recurrence. In the era of combination prevention approaches for HIV infection, it seems quite possible that treatment of BV could be improved through integration of modifiable behavioral factors within more holistic management approaches.
Notes

